Tourmaline Bio Signs Deal for Acquisition by Novartis AG
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 09 2025
0mins
Should l Buy ?
Source: Newsfilter
Acquisition Announcement: Novartis is set to acquire Tourmaline Bio for $48.00 per share, totaling approximately $1.4 billion, reflecting a 59% premium over Tourmaline's stock price prior to the announcement.
Potential of Pacibekitug: The acquisition highlights the promise of Tourmaline's pacibekitug, an anti-IL-6 monoclonal antibody aimed at treating cardiovascular diseases, with expectations for completion in the fourth quarter of 2025, pending regulatory approvals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
